Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.

Ai-Ming Yu1, Jeffrey R Idle, Frank J Gonzalez

  • 1Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Drug Metabolism Reviews
|July 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioengineered miR-148a-3p suppresses glycolysis and amino acid homeostasis in hepatocellular carcinoma cells by regulating multiple solute carrier transporters.

Liver research (Beijing, China)·2026
Same author

Metabolomics-based predictive biomarker discovery for thiopurine response in Crohn disease: Plasma histidine as a promising biomarker.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Design, expression, purification, and application of novel recombinant miR-491 molecules to define the biogenesis and function of miR-491-3p versus -5p in posttranscriptional regulation of UDP-glucuronosyltransferase 1A1.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Efficiency and safety of five different agents for <i>in vivo</i> delivery of novel bioengineered RNAi molecules.

Frontiers in molecular biosciences·2026
Same author

Comparative effectiveness of 7 major human let-7-5p isoforms to modulate target gene expression in liver cells.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Frontiers in pharmacology·2025

Cytochrome P450 2D6 (CYP2D6) is a key enzyme in drug metabolism, with over 80 variants affecting how individuals process medications. Understanding CYP2D6 genetic variations is crucial for personalized drug therapy.

Area of Science:

  • Pharmacogenomics
  • Enzyme kinetics
  • Drug metabolism

Background:

  • Cytochrome P450 2D6 (CYP2D6) is a polymorphic enzyme crucial for metabolizing over 20% of prescription drugs, particularly those acting on the central nervous system and heart.
  • Genetic variations in CYP2D6 lead to distinct metabolic phenotypes, including extensive and poor metabolizers, impacting drug efficacy and safety.
  • Substrates for CYP2D6 are typically organic bases with specific structural features facilitating electrostatic interactions with key residues like Aspartic acid 301 and Glutamic acid 216.

Purpose of the Study:

  • To investigate the role of CYP2D6 genetic polymorphism in drug metabolism and disposition.
  • To establish reliable animal models for studying CYP2D6 function and its clinical implications.
  • To identify endogenous substrates and understand the enzymatic capacity and specificity of CYP2D6.

Related Experiment Videos

Main Methods:

  • Generation of CYP2D6 transgenic mice using a lambda phage clone containing the wild-type gene.
  • Phenotyping of drug metabolism using debrisoquine and sparteine in transgenic and wild-type mice.
  • Identification of endogenous substrates and characterization of their O-demethylation by CYP2D6.

Main Results:

  • CYP2D6 transgenic mice demonstrated enhanced metabolism and disposition of debrisoquine, serving as models for human extensive metabolizers.
  • Wild-type mice served as controls, mimicking human poor metabolizers, validating the animal model's utility.
  • Endogenous 5-methoxyindole-thylamines were identified as high-affinity CYP2D6 substrates, highlighting its role in psychoactive tryptamine interconversions.

Conclusions:

  • The developed transgenic mouse model provides a valuable tool for studying CYP2D6 polymorphism in drug discovery, development, and clinical practice.
  • Understanding CYP2D6 variations is essential for optimizing individualized drug therapy and predicting patient responses.
  • CYP2D6 plays a significant role in the metabolism of endogenous compounds, potentially influencing neurotransmitter pathways like the serotonin-melatonin cycle.